CBB, I don’t disagree that Vascepa is best-suited in the hands of BP. However, Denner still wants to get top dollar for the company, and not just give it away. And that will require more progress towards approvals and reimbursement in EU.
Denner wants to remove as much risk and uncertainty from Amarin before putting it up for sale. I think we need 18 months.
News 
Market Data 
Discover 
